Lifeboat Foundation

(AP) — U.S. health officials Saturday agreed to allow emergency use of a second antibody drug to help the immune system fight COVID-19, an experimental medicine that President Donald Trump was given when he was sickened last month.

The Food and Drug Administration authorized use of the Regeneron Pharmaceuticals Inc. drug to try to prevent hospitalization and worsening disease from developing in patients with mild-to-moderate symptoms.

The drug is given as a one-time treatment through an IV. The FDA allowed its use in adults and children 12 and over who weigh at least 88 pounds (40 kilograms) and who are at high risk of severe illness from COVID-19 because of age or certain other medical conditions.

Pharmaceutical companies Pfizer and partner BioNTech will seek emergency government approval for their coronavirus vaccine on Friday, Health and Human Services Secretary Alex Azar said, paving the way for millions of doses to be distributed within 24 hours.

“We will ship millions of doses of vaccine within 24 hours of FDA approval. So my message is hope and help are on the way,” Azar said Thursday as he announced the pending emergency use application during a White House coronavirus task force briefing.

Pfizer’s German partner BioNTech had said this week that it would seek the emergency approval for the vaccine, which showed 94.5 percent efficacy in clinical trials.

An exercise in pure mathematics has led to a wide-ranging theory of how the world comes together.

Here’s my latest video!

Animal products, including meat, cheese, and eggs contain carnitine and choline, metabolites that are converted by gut bacteria into TMA, which is then converted by the liver into TMAO. Plasma levels of TMAO are associated with an increased risk of disease and death, so should we limit intake of these animal products?

Continue reading “Kidney Function: The Missing Link In The TMAO-Health And Disease Story?” »

What was once a health crisis that Americans feared has evolved into one virtually everyone has experienced up close. That will affect behavior, but in many different ways.

A technology for building quantum computers that has long been sidelined by major companies is gaining momentum. As quantum computing has transformed from academic exercise to big business over the past decade, the spotlight has mostly been on one approach — the tiny superconducting loops embraced by technology giants such as IBM and Intel. Superconductors enabled Google last year to claim it had achieved ‘quantum advantage’ with a quantum machine that for the first time performed a particular calculation that is beyond the practical capabilities of the best classical computer. But a separate approach, using ions trapped in electric fields, is gaining traction in the quest to make a commercial quantum computer.

Amazon is entering the pharmacy business with a new offering called Amazon Pharmacy, allowing customers in the United States to order prescription medications for home delivery, including free delivery for Amazon Prime members.

Amazon has been quietly building out its pharmacy offering for several years after ramping up internal discussions in 2017 and acquiring PillPack in 2018. The pharmacy space is notoriously complex and competitive in the U.S., and Amazon Pharmacy is built in part on PillPack’s infrastructure, including its pharmacy software, fulfillment centers and relationships with health plans.

Amazon Pharmacy, announced Tuesday, is the company’s biggest push yet into $300 billion market, and threatens the dominance of traditional pharmacies like CVS and Walgreens, as well as other large retailers that offer pharmacy services, including Walmart.

The quiet shift in strategy, which brings the Vision Fund’s approach closer to that of a traditional venture capital investor, may ease concerns over big, bold bets going sour, a factor that has left a major gap between SoftBank’s market capitalization and the sum of its investments.

TOKYO — SoftBank Group’s Vision Fund is turning to a new strategy as a global pandemic and government stimulus distort tech valuations: Invest smaller in hopes for bigger returns.

After raising nearly $100 billion and investing $85 billion in high-profile companies like Uber Technologies, WeWork and ByteDance over three years, the Vision Fund is now focusing on making smaller bets in early-stage startups.

Continue reading “SoftBank eyes smaller bets, bigger returns in Vision Fund rethink” »

A team of researchers from Delft University of Technology (TU Delft), Leiden University, Tohoku University and the Max Planck Institute for the Structure and Dynamics of Matter has developed a new type of MRI scanner that can image waves in ultrathin magnets. Unlike electrical currents, these so-called spin waves produce little heat, making them promising signal carriers for future green ICT applications.

MRI scanners can look into the human body in a non-invasive manner. The scanner detects the magnetic fields radiated by the atoms inside, which makes it possible to study the health of organs even though they are hidden underneath thick layers of tissue.

The non-invasive, see-through power of MRI is desirable for many research fields and industries. It could be particularly useful as an imaging tool in nanotechnology and the chip industry. Being able to detect signals in computer chips and other nanodevices would facilitate optimizing their performance and reducing their heat production. However, the millimeter resolution of conventional MRI is insufficient to study chip-scale devices. A team of researchers led by TU Delft have now developed a new method for sensing magnetic waves at the sub-micrometer scale.